A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

NCT ID: NCT02682238

Last Updated: 2023-05-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-08
• Study Completion Date: 2016-10-04

Brief Summary

To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.

Detailed Description

This is a Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects with Palmar Hyperhidrosis.

Participating subjects will apply either BBI-4000 15% or vehicle gel topically to the palms of both hands once daily for 4 consecutive weeks. The 4 week treatment period will be followed by a 2 week follow-up period.

Safety and tolerability will be assessed through collection of vital signs, adverse events, assessment of local skin responses, ECG, UPT and blood sampling.

Efficacy will be assessed through gravimetric sweat assessments as well as through the Hyperhidrosis Disease Severity Scale (HDSS).

Conditions

Hyperhidrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

BBI-4000, 15%

15% BBI-4000 (sofpironium bromide) topical gel

Group Type: EXPERIMENTAL

BBI-4000, 15%

Intervention Type: DRUG

Vehicle

Vehicle (placebo) gel

Group Type: PLACEBO_COMPARATOR

Vehicle gel

Intervention Type: OTHER

Interventions

BBI-4000, 15%

Intervention Type: DRUG

Vehicle gel

Intervention Type: OTHER

Other Intervention Names

Placebo gel

Eligibility Criteria

Inclusion Criteria

• Diagnosis of primary palmar hyperhidrosis
• HDSS of 3 or 4 at baseline
• Gravimetric test at baseline indicating at least 100 mg of sweat production at rest in each palm and a sum of at least 250 mg in both palms, in 5 minutes (room temperature)
• Symptoms of at least 6 months' duration
• Females of childbearing potential must agree to use a medically acceptable method of contraception while participating in the study

Exclusion Criteria

• Any skin or subcutaneous tissue conditions of the palms, other than hyperhidrosis
• Prior use of any prohibited medication(s) or procedure(s) within specified timeframe for the treatment of palmar hyperhidrosis, including:

1. Botulinum toxin to the palmar area within 9 months of baseline visit

2. Iontophoresis within 30 days of baseline visit

3. Palmar thermolysis, sympathectomy or surgical procedures of the palmar area any time in the past

4. Serotonergic agonist within 30 days of baseline visit

5. Any topical prescription treatment for hyperhidrosis within 30 days of baseline visit

6. Any over-the-counter topical antiperspirant/deodorant within 7 days of baseline visit

• Use of anticholinergic agents within 30 days of baseline visit
• Any oral or topical homeopathic or herbal treatment within 30 days of baseline visit
• Use of any cholinergic drug within 30 days of baseline visit
• Use of any anti-anxiety and/or anti-depressant, amphetamine products or drugs with known anticholinergic side effects
• Hyperhidrosis secondary to any known cause
• Subjects with history of unstable type 1 or type 2 diabetes mellitus or thyroid disease, history of renal impairment, hepatic impairment, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, benign prostatic hyperplasia (BPH), neurological conditions, psychiatric conditions, Sjögren's syndrome, Sicca syndrome, or cardiac abnormalities that may alter normal sweat production or may be exacerbated by the use of anticholinergics.
• Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation.
• Pregnant or lactating women.
• Use of an investigational drug within 30 days prior to the baseline visit.
• Any major illness within 30 days before the screening examination.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Botanix Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

TCR Medical Corporation

San Diego, California, United States

International Dermatology Research, Inc.

Miami, Florida, United States

Shideler Clinical Research Center

Carmel, Indiana, United States

Saint Louis University Dermatology

St Louis, Missouri, United States

Virginia Clinical Research, Inc.

Norfolk, Virginia, United States

Countries

United States

Other Identifiers

BBI-4000-CL-202

Identifier Type: -

Identifier Source: org_study_id